• Return to Headlines

Relatively Low Sales per Share Detected in Shares of Vital Therapies in the Biotechnology Industry (VTL, ZFGN, ACHN, AIMT, ATRA)

By Nick Russo

Below are the three companies in the Biotechnology industry with the lowest sales per share. Sales per share is a valuable metric in comparing relative value for companies in the same industry.

Vital Therapies ranks lowest with a sales per share of $0.00. Zafgen Inc is next with a sales per share of $0.00. Achillion Pharma ranks third lowest with a sales per share of $0.00.

Aimmune Therapeu follows with a sales per share of $0.00, and Atara Biotherape rounds out the bottom five with a sales per share of $0.00.

SmarTrend recommended that subscribers consider buying shares of Atara Biotherape on November 19th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $14.17. Since that recommendation, shares of Atara Biotherape have risen 14.3%. We continue to monitor Atara Biotherape for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest sales per share vital therapies zafgen inc achillion pharma aimmune therapeu atara biotherape

Ticker(s): VTL ZFGN ACHN AIMT ATRA